Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

67.40 +0.42 (+0.63%)
Streaming Delayed Price Updated: 12:15 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Here's What Crushed Exelixis' Earnings
R&D spending is hurting earnings, but long-term investors shouldn't be worried. 
Via The Motley Fool
Is Editas the Best Genetics Stock to Buy?
There are some big opportunities in the gene editing space. 
Via The Motley Fool
A Better Switch
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... 
Via Benzinga
Bristol-Myers Squibb Co Is Slipping, Watch This Bounce Level
Traders should watch for very strong support around the $60.00 area. This level is where the shares were defended in early March 2021. 
Via Talk Markets
Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution
Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate-648 trial, which had two Opdivo-based treatment combinations — Opdivo... 
Via Benzinga
Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters
Bristol Myers Squibb Co (NYSE: BMY) was sued for $6.4 billion for allegedly delaying approval for Breyanzi cancer drug to avoid payments to shareholders of the... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,... 
Via Benzinga
Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or... 
Via Benzinga
Bristol Myers' Opdivo-Yervoy Combo Approved In Europe, Canada For Malignant Pleural Mesothelioma
The regulatory authorities in Europe and Canada have approved Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) plus Yervoy (... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Anika Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
From Bristol Myers Squibb
Via Business Wire
I’d Have To Disagree With Buffett’s Latest Stock Sells (As He Sells, I Buy)
Warren Buffett oversees a common stock portfolio for Berkshire Hathaway worth almost $300 billion. This portfolio has largely been built by steadily accumulating shares in high-quality businesses over... 
Via Talk Markets
Bristol-Myers' Zeposia Scores FDA Approval For Ulcerative Colitis
The FDA has approved Bristol Myers Squibb & Co's (NYSE: BMY) Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1
From Bristol Myers Squibb
Via Business Wire
2 Top Dividend Stocks for a Better Retirement
They're safe companies that also regularly raise their payouts. 
Via The Motley Fool
Topics Retirement
Exposures Pension
Bristol Myers Squibb to Take Part in Bernstein’s 37th Annual Strategic Decisions Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies
Xencor Inc (NASDAQ: XNCR has entered into a technology license agreement with Bristol-Myers Squibb Co (NYSE: BMY), under which BMY will have non-exclusive access... 
Via Benzinga
Exposures COVID-19
Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
From Xencor, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
2 High-Yield Dividend Stocks for 2021
Why you might want to consider adding these two best-in-class stocks to your portfolio. 
Via The Motley Fool
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ASCO 2021 Highlights
From Bristol Myers Squibb
Via Business Wire
The Bristol Myers Squibb Foundation Announces First Global Cancer Disparities Grants in Brazil
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
Exposures COVID-19
Biotech Stocks Cruise Through The Volatility
The XLV Healthcare Select SPDR is up 10% YTD. 
Via Talk Markets
Bristol Myers Unveils More Positive Data On Ulcerative Colitis Candidate Zeposia
Bristol-Myers Squibb & Co (NYSE: BMY) released positive new data on its ulcerative colitis (UC) candidate Zeposia (ozanimod) at Digestive Disease Week (DDW),... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.